Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722198 | 0.83 | PDPK1 (0.77) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL5802837 | 0.82 | PDPK1 (0.50) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL5802835 | 0.82 | PDPK1 (0.50) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL6850509 | 0.79 | LOXL2 (0.62) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL29793674 | 0.79 | PDPK1 (0.55) | PDPK1LOXL2ADRB2CYP2A6HDAC2 | |
| SCHEMBL4541318 | 0.79 | PDPK1 (0.55) | PDPK1LOXL2ADRB2CYP2A6HDAC2 | |
| SCHEMBL6850518 | 0.78 | PDPK1 (0.53) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL21791658 | 0.78 | LOXL2 (0.71) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| SCHEMBL466424 | 0.78 | PDPK1 (0.63) | PDPK1LOXL2ADRB2CYP2A6ABL1 | |
| 2-Phenylthiazole SCHEMBL28126546 | 0.76 | PDPK1 (0.78) | PDPK1LOXL2ADRB2CYP2A6ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025090793-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11857550-B2 | Benzathine analogs | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-01-02 | — | — | US | disclosed |
| CN-116969904-A | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0929553-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| CN-1216539-A | Heterocyclic azahexane derivatives with antiviral activity | NOVARTIS AG (CH) | 1999-05-12 | — | — | CN | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0900210-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | Novartis AG (CH) | 1999-03-10 | — | — | EP | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998014450-A1 | PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| WO-1997040029-A1 | ANTIVIRALLY ACTIVE HETEROCYCLIC AZAHEXANE DERIVATIVES | NOVARTIS AG (CH) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857550-B2 | Benzathine analogs | HDAC10, CFTR, HBB | PDPK1 4874/4885LOXL2 2670/4885ADRB2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.